AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular ...
Imsidolimab demonstrated rapid and sustained efficacy with 6 of 8 (75%) generalized pustular psoriasis (GPP) patients achieving the primary endpoint at week 4 and week 16Early reduction of erythema with
United States Johann Gudjonsson Paul Lizzul Bristol Myers Squibb Japanese Dermatology Association European Academy Of Dermatology
Source: kulr8.com